Loading
OmniAb
OmniAb, Inc. operates as a biotech company. The Company develops therapeutic antibody discovery platform that provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. OmniAb serves biopharmaceutical companies and research institutions worldwide.
Funding
Every round, secondary, debt facility or acquisition involving OmniAb that Lounge tracks, newest first.
No rounds recorded yet.
Paid members see the full deals desk — every AI round and exit, filterable by type, sector and country, with investors and reported ARR, plus CSV exports. Developer membership is $9/mo.
See plans →Log inKey numbers
—
0
—
—